[1]Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody[J].Hum Mol Genet, 1993, 2 (11) ∶1847-1851.
|
[2] Tacket CO, Roy MJ, Widera G, et al. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device[J]. Vaccine, 1999, 17 (22) ∶2826-2829.
|
[3]Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+T cells, T helper cells, and protective levels of antibody in human by particle-mediated administration of a hepatitis B virus DNA vaccine [J]. Vaccine, 2000, 19 (7-8) ∶764-778.
|
[4]Swain WE, Heydenburg Fuller D, Wu MS, et al. Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B[J]. Dev Biol (Basel) , 2000, 104∶115-119.
|
[5]Michel ML, Pol S, Brechot C, et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future [J]. Vaccine, 2001, 19∶2395-2399.
|
[6]Schmaljohn C, Vanderzanden L, Bray M, et al. Maked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge[J]. J Virol, 1997, 71∶9563-9569.
|
[7]Singh M, Briones M, Ott G, et al. Cationic microparticles: A potent delivery system for DNA vaccines [J]. Proc Natl Acad Sci USA, 2000, 97∶811-816.
|
[8]Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic Tlymphocytes in humans by a malaria DNA vaccine [J]. Science, 1998, 282∶476-480.
|
[9]MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for trestment of human immunodeficiency virus type 1 infection:safety and host response[J]. J Infect Dis, 1998, 178∶92-100.
|
[10]Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients [J]. Lancet, 1998, 351∶1320-1325.
|
[11]Guidotti LG, Rochford R, Chung J, et al. Viral Clearance without destruction of infected cells during acute HBV infection [J]. Science, 1999, 284∶825-829.
|
[12]Haworth R, Pilling AM. The PCR assay in the preclinical safety evaluation of nucleic acid medicines[J]. Hum Exp Toxicol, 2000, 19∶267-276.
|